Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer

  • Peter H. O'Donnell
  • , Matthew I. Milowsky
  • , Daniel P. Petrylak
  • , Christopher J. Hoimes
  • , Thomas W. Flaig
  • , Nataliya Mar
  • , Helen H. Moon
  • , Terence W. Friedlander
  • , Rana R. McKay
  • , Mehnet A. Bilen
  • , Sandy Srinivas
  • , Earle F. Burgess
  • , Chethan Ramamurthy
  • , Saby George
  • , DM Geynisman
  • , Sergio Bracarda
  • , Delphine Borchiellini
  • , Lionnell Geoffrois
  • , Jose Pablo Maroto Rey
  • , Christiano Ferrario
    • Anne-Sophie Carret, Yao Yu, Maria Guseva, Blanca Hornet Moreno, Jonathan E. Rosenberg

Research output: Contribution to journal › Article › peer-review

146 Scopus citations

Fingerprint

Dive into the research topics of 'Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science